+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
FEMALE
ID04517838

Study of Immune Responses to Anti-HER2 Treatments in Women with HER2-Positive Breast Cancer Stage I-IV

Led by Mayo Clinic · Updated on 2026-06-16

230

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

The trial investigates immune responses in patients with HER2-positive breast cancer stages I through IV who are receiving anti-HER2 therapies such as trastuzumab, pertuzumab, lapatinib, or neratinib. Researchers aim to understand how specific T-cell and antibody responses relate to clinical outcomes and the immune activity within tumor tissue during these treatments. This study also explores additional immune markers and genetic factors that may influence treatment response and disease recurrence. Participants are assigned to one of two groups the Blood & Tissue Cohort or the Tissue-Only Cohort. In the Blood & Tissue Cohort, patients with stage I-III disease and certain stage IV patients provide blood samples at baseline, at 8 and 16 weeks after starting therapy, and at the time of disease recurrence or progression. Tissue samples from previous biopsies or surgeries are collected for all patients. The Tissue-Only Cohort includes patients with stage I-IV breast cancer who have received or completed anti-HER2 therapy, with tissue samples collected for analysis. During the study, participants provide blood and tumor tissue samples according to their assigned group. Researchers evaluate specific immune responses such as HER2 T-cell and antibody activity, monitoring changes over time and their association with clinical responses up to 16 weeks. The study measures the relationship between immune markers and patient outcomes, including progression-free and overall survival. This observational study continues until 2028, gathering data to improve understanding of immune reactions to anti-HER2 therapies.

CONDITIONS

Brief Title

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Research Team

C

Clinical Trials Referral Office

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here